A study was conducted to determine whether a pharmacological dose of insulin-like growth factor (IGF-I), administered with a low dose of growth hormone (GH), could produce an anabolic response in HIV/AIDS patients. The minimum effective GH dose needed, however, is not known. The GH dose selected was about an order of magnitude lower than that usually used for pharmacological treatment of GH deficiency. It was found that the moderate IGF-I dose combined with a low GH dose was insufficient to produce a detectable anabolic response as judged by the measurements of total body potassium (TBK) and total body nitrogen (TBN).
ASJC Scopus subject areas